I am invested in Nemucore because I believe that their focus on coupling therapies with companion diagnostics is a novel way of addressing the cancer problem. Identifying patients for whom individual drugs may have the most positive outcomes is a marked improvement over the hit-or-miss approaches of the past, and I believe that customizable treatment is the future. I also appreciate that Nemucore’s focus on blood cancers specifically is a unique business model. I have known the CEO, Tim Coleman, for over 25 years and know his tenacity when pursuing solutions to tough problems well. I also appreciate his focus on assembling top-notch staff and teaming partners in pursuing a successful path forward for Nemucore.
Molecularly guided therapies have changed the outcome for a growing proportion of cancer patients, but this approach is still largely untapped for the majority of individuals with acute myeloid leukemias and myelodysplastic syndromes. NMI-900 therapy coupled with a novel RNA biomarker provides a new strategy for helping a larger portion of patients with a variety of malignant blood disorders.